Metabolic Drivers of MASLD/MASH: Understanding the Disease and Identifying At-Risk Patients

Program Description

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are becoming more common as rates of obesity, type 2 diabetes, and other cardiometabolic conditions continue to rise. As a result, more patients are at risk for advanced fibrosis, cirrhosis, and other serious liver-related complications. Because many patients remain asymptomatic until later stages, effective management depends on early risk recognition and practical, noninvasive evaluation. Ongoing challenges include delayed diagnosis, inconsistent screening practices, and the terminology shift from NAFLD/NASH to MASLD/MASH, which may affect clinical communication during this transition period. This webinar will review how pharmacists are well positioned to help identify high-risk patients, encourage appropriate screening and follow-up, and reinforce lifestyle and cardiometabolic risk-reduction strategies. This symposium is the first in the MASLD/MASH curriculum.

Target audience: Specialty and health-system pharmacist
Type of activity: Application
Release date: May 31, 2026
Expiration date: May 31, 2027
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the epidemiology, metabolic drivers, clinical presentation, and disease burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)
• Identify clinical indicators and high-risk patient populations that may warrant further evaluation for MASLD/MASH
• Apply current guideline recommendations to support screening awareness, patient education, and referral for appropriate evaluation